3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Stomach Neoplasms
6
Pancreatic Neoplasms
5
Colonic Neoplasms
5
Breast Neoplasms
5
Prostatic Neoplasms
4
Colorectal Neoplasms
4
Urinary Bladder Neoplasms
3
Rectal Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Hematologic Neoplasms
3
Esophageal Neoplasms
3
Biliary Tract Neoplasms
3
Neoplasm Metastasis
2
Multiple Myeloma
2
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Skin Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Interventions
pembrolizumab
3
Nivolumab
3
Ipilimumab
2
Interleukin-2
2
Drug Therapy
2
Biopsy
2
pertuzumab
1
osimertinib
1
montanide ISA 51
1
liposomal doxorubicin
1
cobimetinib
1
brodalumab
1
atezolizumab
1
Trastuzumab
1
Tissue Banks
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Radiotherapy
1
Radiosurgery
1
Quality of Life
1
Psychiatric Rehabilitation
1
Poly I-C
1
Photochemotherapy
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oxaliplatin
1
Observation
1
Molecular Diagnostic Techniques
1
Mass Screening
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
pertuzumab
×
Gastrointestinal
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled